BioSpace News Archive

Aeroflow Healthcare, an Inc. 5000 fastest growing company, today announced the launch of Aeroflow Naturals, a division of products designed to offer patients high-quality cannabidiol (CBD) products as natural solutions that may assist with a variety of conditions.

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination (LCD) for the myPath® Melanoma test to help physicians provide a definitive diagnosis when a suspicious skin lesion is equivocal based upon histopathology.

The U.S. Food and Drug Administration today allowed marketing of a new device, ClearMate, intended to be used in an emergency room setting to help treat patients suffering from carbon monoxide poisoning

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc. (Cyclerion) has been declared effective by the U.S. Securities and Exchange Commission (SEC).

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the company’s New Drug Application (“NDA”) for its higher naloxone injection product candidate for the treatment of opioid overdose.

Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, today announces the appointment of Dr David Chiswell OBE as a Non-Executive Director of Bond 2 Development 2 GP,

CARB-X announced today it has signed a partnership agreement with Germany’s Federal Ministry of Education and Research (BMBF) to invest €39 million over four years in the early development of antibiotics, vaccines, and diagnostics to combat drug-resistant bacteria

Karyopharm Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for selinexor.

Matinas BioPharma Holdings, Inc. announced that it has commenced an underwritten public offering of its common stock.

Linda Sampson Nominates Marcel LeBlanc, VP of NorCan To Hold Her Board Position, issued 14-Mar-2019 by Liht Cannabis Corporation over CNW, we are advised by the company that there is a revision to the end of the first sentence.